Phase I Trial Update

A new phase I trial has shown that a small, 28-amino-acid peptide called p28, which stabilizes p53 (encoded by TP53) to protect it from degradation, is well-tolerated in patients with advanced solid tumours. The work—a first-in-class, first-in-human trial—also demonstrated that some tumour control could be achieved. Targeted therapies: One step closer to drugging p53.

Razzak M. Nat Rev Clin Oncol. 2013 10(5):246. doi: 10.1038/nrclinonc.2013.43.